Table 3.

Sensitivities of biomarkers at various specificity levels

	70% Specificity		80% Specificity		90% Specificity		95% Specificity
	Cutoff	Sensitivity (95% CI)	Cutoff	Sensitivity (95% CI)	Cutoff	Sensitivity (95% CI)	Cutoff	Sensitivity (95% CI)
All Subjects:
freePSA (ng/ml)	0.49	0.72 (0.69, 0.78)	0.67	0.46 (0.43, 0.53)	0.90	0.31 (0.28, 0.38)	1.31	0.14 (0.12, 0.2)
[−2]proPSA (pg/ml)	9.93	0.61 (0.58, 0.68)	12.58	0.47 (0.44, 0.54)	17.22	0.29 (0.26, 0.35)	20.79	0.16 (0.14, 0.22)
phi	28.05	0.62 (0.59, 0.69)	31.58	0.53 (0.5, 0.6)	36.45	0.42 (0.39, 0.49)	42.27	0.29 (0.26, 0.36)
%freePSA*	25.23	0.7 (0.67, 0.76)	22.75	0.62 (0.59, 0.69)	18.87	0.53 (0.5, 0.6)	15.58	0.34 (0.31, 0.41)
%[−2]proPSA*	1.72	0.43 (0.4, 0.5)	1.53	0.33 (0.3, 0.4)	1.31	0.19 (0.17, 0.25)	1.10	0.11 (0.09, 0.16)
DKK1 (ng/ml)*	0.84	0.31 (0.28, 0.38)	0.68	0.21 (0.19, 0.27)	0.53	0.14 (0.12, 0.2)	0.40	0.05 (0.04, 0.09)
NEM (ng/ml)	0.28	0.37 (0.34, 0.44)	0.64	0.25 (0.22, 0.31)	1.93	0.07 (0.06, 0.12)	4.36	0.04 (0.03, 0.08)
PSA 2–10 ng/ml:
freePSA (ng/ml)*	0.68	0.49 (0.42, 0.64)	0.52	0.24 (0.19, 0.39)	0.39	0.07 (0.04, 0.18)	0.28	0.02 (0.01, 0.11)
[−2]proPSA (pg/ml)*	10.00	0.33 (0.27, 0.48)	8.05	0.19 (0.14, 0.33)	5.83	0.05 (0.03, 0.15)	5.46	0.04 (0.02, 0.14)
phi	36.88	0.46 (0.39, 0.61)	39.09	0.38 (0.32, 0.53)	43.47	0.27 (0.22, 0.43)	51.06	0.22 (0.16, 0.36)
%freePSA*	19.46	0.61 (0.54, 0.75)	17.70	0.51 (0.44, 0.66)	14.08	0.29 (0.23, 0.44)	7.37	0.04 (0.02, 0.13)
%[−2]proPSA	1.85	0.44 (0.38, 0.6)	2.12	0.3 (0.24, 0.46)	2.45	0.19 (0.14, 0.33)	2.59	0.15 (0.11, 0.29)

^*Marker is under-expressed in cancer cases.